G9836 – Reason for not administering trastuzumab documented (e.g. patient declined, patient died, patient transferred, contraindication or other clinical exclusion, neoadjuvant chemotherapy or radiation not complete)

Long description

Reason for not administering trastuzumab documented (e.g. patient declined, patient died, patient transferred, contraindication or other clinical exclusion, neoadjuvant chemotherapy or radiation not complete)

Short description

Rsn no trast given doc

Pricing indicator

00 Not separately priced by Part B (bundled, not covered or Part A only)

Medicare coverage

C Carrier judgment – coverage decided by the Medicare contractor

BETOS category

Z2 Undefined codes

Added

January 1, 2017

Last change

January 1, 2021 – No change

Termination date

December 31, 2020

Nearby G codes

• G9828 – Her2-targeted therapies administered during the initial course of treatment
• G9829 – Breast adjuvant chemotherapy administered
• G9830 – Her-2/neu positive
• G9831 – Ajcc stage at breast cancer diagnosis = ii or iii
• G9832 – Ajcc stage at breast cancer diagnosis = i (ia or ib) and t-stage at breast cancer diagnosis = t1c
• G9833 – Patient transfer to practice after initiation of chemotherapy
• G9834 – Patient has metastatic disease at diagnosis
• G9835 – Trastuzumab administered within 12 months of diagnosis
• G9837 – Trastuzumab not administered within 12 months of diagnosis
• G9838 – Patient has metastatic disease at diagnosis
• G9839 – Anti-egfr monoclonal antibody therapy
• G9840 – Ras (kras and nras) gene mutation testing performed before initiation of anti-egfr moab
• G9841 – Ras (kras and nras) gene mutation testing not performed before initiation of anti-egfr moab
• G9842 – Patient has metastatic disease at diagnosis
• G9843 – Ras (kras or nras) gene mutation
• G9844 – Patient did not receive anti-egfr monoclonal antibody therapy